NEW YORK (GenomeWeb News) – Charles River Laboratories has completed its purchase of the BioFocus and Argenta service division operations from Galapagos for up to €134 million ($184 million). As part of the deal announced in March, Charles River paid Galapagos €129 million upfront and will pay potentially up to another €5 million upon the achievement of a revenue target 12 months after the closing of the deal.
IntegraGen has reached an agreement with Pfizer that provides the drugmaker access to IntegraGen's proprietary molecular signature for hepatocellular carcinoma for its evaluation. The 56-gene signature is intended to predict the clinical prognosis of patients with hepatocellular carcinoma and categorize them into six classifications based on the molecular characteristics of their liver tumors. Financial terms were not disclosed.
Eurofins MWG Operon and Eurofins Medigenomix are being brought together under the new Eurofins Genomics brand, which will be the genomics division of the Eurofins Scientific Group. Eurofins MWG Operon provided genomic services, while Eurofins Medigenomix focused on applied solutions in DNA and RNA analysis. Eurofins Genomics operates R&D and production sites in the US, Germany, India, and Japan. Among the services it provides are next-generation sequencing, genotyping, and gene expression.
Agilent Technologies announced a quarterly dividend of $.132 per share of common stock that will be paid on April 23 to shareholders of record as of the close of business on April 11.
UK healthcare and life science research firm Source BioScience has opened US offices in Los Angeles and Atlanta. The Los Angeles office offers services that include Source Bio's Overnight Service for DNA sequencing, while the Atlanta office houses more than 20 million cDNA clones. Both facilities will provide pharma and biopharma stability storage services.
ProteinSimple has opened an office in Tokyo and hired Satoshi Ogino as general manager for Japanese sales.
Spanish open-source software firm Kanteron Systems has joined the Global Alliance for Genomics and Health, an international coalition formed to enable the sharing of genomic and clinical data. Among the other members of the alliance are the Broad Institute, Mayo Clinic, IBM, and Google.
Proove Biosciences has joined the Personalized Medicine Coalition. The Irvine, Calif.-based firm also said that its Founder and CEO Brian Meshkin has been appointed to the coalition's Science Policy and Public Policy committees.
In Brief This Week is a Friday column containing news items that our readers may have missed during the week.